at the time of randomization; life-table analysis of stroke, stroke-related mortality and total mortality; and occurrence of TIAs within 6 months after treatment assignment.
THE ASPIRIN in Transient Ischemic Attacks (AITIA) Study consisted of two simultaneous clinical trials designed to test the effectiveness of aspirin in the treatment of arterial thromboembolism and its sequelae. One trial evaluated aspirin as a drug therapy for the medical management of the disease; the second evaluated aspirin as a drug therapy adjunct to surgical reconstruction of the carotid artery.
The medical study was a cooperative double-blind trial of 178 patients with carotid transient ischemic attacks (TIAs) who were assigned randomly to an aspirin or placebo regimen. The surgical trial consisted of 125 patients with TIAs and one or more visualized and accessible carotid lesions, who had reconstructive operations and were then randomly allocated to an aspirin or placebo regimen. All patients were followed to determine the incidence of subsequent TIAs, cerebral or retinal infarction or death. Details and major results of these studies have been reported previously. 1' 2 The objectives of the AITIA Study were to determine whether oral administration of aspirin would result in the reduction or prevention of TIAs of the hemispheric type and of transient monocular blindness or partial blindness (amaurosis fugax), and whether oral administration of aspirin would result in a reduction of cerebral infarction and stroke-related mortality. Analyses of the data covered three major areas: baseline characteristics of the study populations at the time of randomization; life-table analysis of stroke, stroke-related mortality and total mortality; and occurrence of TIAs within 6 months after treatment assignment.
Results

Baseline Comparisons
Twenty-one baseline characteristics of the medical and surgical groups are presented in tables 1 and 2. Demographic attributes and clinical histories describe the patient population and provide a basis for comparison of the treatment groups. In general, the randomization process produced homogeneous groups for the comparison of aspirin and placebo treatments. Life-table Analysis   Table 3 presents the 24-month life table for the group treated medically. The end points are death from any cause, cerebral infarction or retinal infarction. The differences in the cumulative event rates provide one measure of the efficacy of the aspirin therapy.
In the medical group, 32 events (13 aspirin, 19 placebo) were reported. There were three deaths (one intracerebral hemorrhage, two myocardial infarctions) in the aspirin group, whereas there were eight deaths in the placebo group. These included one cancer death, one cerebral infarct, two brain-stem infarcts and four cardiovascular deaths.
Although the relative risk of an event was consistently greater than one throughout the 24-month period (table 3) , the log-rank test for differences between the aspirin and placebo group was not significant at the 5% level. Restricting end point events to fatal or nonfatal cerebral or retinal infarctions yielded a similar comparison. However, the data were equally consistent with a one-third reduction in risk of a fatal or nonfatal cerebral or retinal infarction by the use of V-90 Occurrence of TIAs To address the major objective of the study, the occurrence of TIAs was included in the evaluation of the treatments. An outcome was considered unfavorable if the patient died during the first 6 months of follow-up, survived the first 6 months but had a cerebral or retinal infarction during that period or survived and did not have a cerebral or retinal infarction during the first 6 months, but the number of TIAs during that period was greater than or equal to the number of TIAs reported in the 3 months before randomization. The 6-month period required an approximate 50% reduction in reported TIAs to judge a treatment successful. All the remaining patients who completed 6 months of follow-up were classified as favorable. When all of these variables were considered simultaneously, the difference between the aspirin and placebo groups remained significant. A guaiac test on a stool specimen was made at each follow-up visit, and careful surveillance was maintained for any hemorrhagic complications. In the medical and surgical groups combined, nine patients receiving aspirin had evidence of hemorrhage or the development of a peptic ulcer that, in some cases, appeared to be related to the aspirin. Among these nine, three developed skin ecchymoses. The study medication was discontinued for a short interval and then resumed. Two of the three continued in the trial, but the third patient had recurrence of the ecchymoses when the medication was resumed. Three patients who developed peptic ulcers and two who had upper gastrointestinal bleeding had to be withdrawn from the trial. A 59-year-old black woman with hypertension died of an intracerebral hemorrhage during the fifth month of follow-up; despite antihypertensive medication, her blood pressure had been recorded as high as 194/120 mm Hg.
One person in the placebo group developed a possible duodenal ulcer and was withdrawn from the study. Guaiac-positive stools were obtained in approximately equal numbers in the aspirin and placebo groups.
Comparison of AITIA Study with Canadian Study The CCSG and the AITIA trials were different in terms of both the design and methods and the type of patients admitted, but their findings were similar. The CCSG admitted patients over a period of 56 months, whereas the AITIA trial studied patients for 31 months. The Canadians had a study sample of 585 patients, vs 178 in our medical group and 125 in our surgical group. Both studies support the conclusion that aspirin is of benefit in patients with threatened stroke, although the benefit in the Canadian study was confined to male patients. We did find that the difference in favor of aspirin was mainly in patients with a history of multiple TIAs, but this finding was not apparent in the Canadian trial.
Our published results did not contain separate analyses for men and women. However, in light of the results from the CCSG indicating that, as a preventive of stroke or death, aspirin is effective in males only, the AITIA results were reexamined with regard to the sex of the subjects.
The cumulative event rates for 2 years in our patients according to sex are summarized in table 7. Males who received aspirin had a lower cumulative event rate than males who received placebo, but females showed practically no difference between the aspirin and placebo regimens. For the "hard" end points of stroke or death, the AITIA and CCSG results were similar. For comparison, the reduced risk due to aspirin was calculated for males, females, and both sexes combined (table 8) .
A major finding from the AITIA trial was that after 6 months the aspirin group had a smaller proportion of patients whose outcome was classified as unfavorable; i.e., patients died, had a cerebral or retinal infarction or failed to have a 50% reduction in the TIA rate during the first 6 months of treatment. Both males and females taking aspirin had a larger proportion classified as favorable (table 9) . Statistical analysis showed that females overall had a greater proportion of favorable outcomes than males, but the effect of aspirin did not differ according to sex.
Would the inclusion of TIAs as an outcome yield similar results in the CCSG study? The CCSG reported an analysis of the outcomes of stroke, death or continuing TIAs for the two sexes combined but not for each sex separately. Further analysis showed that there was no difference between the two sexes when the same outcome criteria were used and separate analysis for each group undertaken. This was No significant sex by treatment interaction (x2 = 0.170; 0.5 < p < 0.75).
*The CCSG outcome of stroke, death or continuing TIA is not precisely the same as our "unfavorable" classification because the last is restricted to the first 6 months of observation and adjusts for the number of TIAs in the 3 months before randomization. Both types of outcomes do, however, include a measure of negative TIA experience, and on this basis, are considered appropriate for comparison. V-95 study protocol provided for the admission of persons who had a minor deficit that was prolonged beyond the usual 24-hour limit. These patients were fairly equally divided between the aspirin and placebo groups. At the close of the study, the group that had had a deficit on admission compared very closely with the total patient population in percentages of favorable and unfavorable responses.
Clinical trials often provide some answers, but they also raise many new questions. To gain new insight into some of these questions, we are involved in a trial of aspirin and dipyridamole. The effects of "low-dose" aspirin (300 mg daily) and "high-dose" aspirin (600 mg twice daily) are being studied in the United Kingdom.
